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PAPER
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Objectives: It has been suggested that autoimmunity to peripheral myelin proteins is involved in the
pathogenesis of Guillain-Barre´ syndrome (GBS) and chronic inflammatory demyelinating polyradiculo-
neuropathy (CIDP). We aimed to compare reactivity of peripheral blood mononuclear cells (PBMC) to
antigens of peripheral myelin proteins in patients with GBS and patients with CIDP with that of healthy
controls and patients with other non-immune mediated neuropathies (ON).
Methods: We prepared PBMC from blood from 83 healthy controls and from 64 patients with GBS, 54
with CIDP, and 62 with ON. PBMC were tested in antigen specific proliferation assays against peptides
from myelin proteins P0, P2, PMP22, and myelin basic protein (MBP), which is identical to myelin P1, and
against whole human MBP. Interferon-gamma (IFN-c) and interleukin (IL)-5 enzyme linked immunospot
(ELISPOT) assays were also performed in some subjects to assess spontaneous and peripheral myelin
antigen specific PBMC cytokine secretion.
Results: Antigen specific PBMC proliferation assays showed no significant elevation of peptide specific T
cell responsiveness in patients with GBS or CIDP compared with healthy controls or patients with ON.
Levels of spontaneous ELISPOT IFN-c secretion were increased in patients with GBS and significantly
increased in those with CIDP compared with healthy controls and patients with ON. No convincing
differences in antigen specific ELISPOT IFN-c secretion levels to individual peptides were detectable in
patients with GBS. The proportion of patients with CIDP with an increased number of PBMC producing
IFN-c in response to peptide PMP-2251–64 was significantly increased compared with healthy controls and
patients with ON. No significant differences in antigen specific ELISPOT IL-5 secretion levels were
detectable in patients with GBS or CIDP compared with controls, but levels of spontaneous IL-5 secretion
were significantly higher in patients with CIDP than in healthy controls or patients with ON.
Conclusions: Although the lack of significantly increased antigen specific PBMC proliferation in GBS and
CIDP does not support a role for T cells, the more sensitive ELISPOT technique detected increased numbers
of PBMC secreting IFN-c spontaneously in 25% of patients with GBS, providing further evidence for a role
of T cells in the immunopathology of GBS. Increased numbers of spontaneous IFN-c and IL-5 secreting
cells, and increased IFN-c secretion in response to PMP-2251–64, in patients with CIDP provide further
evidence for a role of myelin specific T cells in CIDP.
T
he most common form of Guillain-Barre´ syndrome
(GBS) seen in Australia is acute inflammatory demyeli-
nating polyradiculoneuropathy (AIDP), an acute mono-
phasic disease of the peripheral nervous system causing
ascending limb weakness. Chronic IDP (CIDP) is a similar
disorder, with a chronic relapsing or chronic progressive
disease course. Although differing in clinical course, GBS and
CIDP have similar pathological findings of primary demye-
lination and infiltration of peripheral nerves with macro-
phages and T cells.1 2 The pathogenesis of GBS and CIDP is
thought to be due to activation of autoimmune mechanisms
by exposure to environmental antigens.3 Infections and
immunisations are commonly found to precede episodes of
GBS,4 5 and it is thought that these may trigger immune
responses that cross react with antigens in peripheral nerves.3 6 7
Immune reactivity to peripheral myelin proteins
Previous studies have attempted to identify peripheral nerve
myelin antigen(s) that are the targets of immune attack in
GBS and CIDP, including P0, P1 (identical to myelin basic
protein (MBP) in the CNS), P2, and PMP-22.8
Some studies have found that patients with GBS and some
patients with CIDP have elevated levels of antibody9 10 and T
cells specific for P2,11–13 although other studies disagree.14 15
There have been reports of increased antibody to P0 in a
minority of patients with GBS,9 10 16 and in one third of
patients with CIDP.17 Increased T cell reactivity to P0 in
patients with GBS has also been reported.12 Antibody
responses to PMP-22 have been described in both inflam-
matory and non-inflammatory neuropathy,18 19 although this
remains controversial.16 There are no previous studies of T cell
reactivity to PMP-22 in either GBS or CIDP.
Evidence for T cell involvement in GBS and CIDP
Because of the improvement of patients after therapy with
plasma exchange and intravenous immunoglobulin,20 anti-
body responses are thought to be important in GBS and
CIDP. However, T cells are also likely to play a role in GBS
Abbreviations: AIDP, acute inflammatory demyelinating
polyradiculoneuropathy; CIDP, chronic inflammatory demyelinating
polyradiculoneuropathy; EAN, experimental autoimmune neuritis;
ELISPOT, enzyme-linked immunospot; GBS, Guillain-Barre´ syndrome;
IFN-c, interferon-gamma; IL5, interleukin 5; MBP, myelin basic protein;
ON, other non-immune mediated neuropathies; PBMC, peripheral blood
mononuclear cells; SFC, spot forming cell; SI, stimulation index; TNF,
tumour necrosis factor
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and CIDP. T cell help is an important prerequisite for B cell
maturation and antibody production. T cells are found in the
peripheral nerves of some subjects with GBS21 22 and CIDP.23
Increased numbers of circulating activated T cells in patients
with GBS,24 25 altered proportions of T cell subsets,25 raised
circulating levels of IL-2 and soluble IL-2 receptor,26–28 and
oligoclonal expansion of T cells bearing particular T cell
receptor Vb and Vd genes29 all support a role for T cells in GBS
and CIDP. Furthermore, experimental autoimmune neuritis
(EAN), an animal model of GBS, which can be induced by
inoculation of susceptible animals with myelin proteins, or
peptides from P2,30 P0,31–34 or PMP-22,35 can also be passively
transferred by activated T cells specific for peripheral myelin
antigens.36
T cell Th1 versus Th2 cytokine secretion profiles
The spectrum of cytokines produced by T cells has a strong
influence on the outcome of immune responses. Human
CD4+ helper T cells can be divided into two categories. (a)
Th1 cells produce the cytokines IL-2, IFN-c, tumour necrosis
factor (TNF)-a, and TNF-b. Th1 responses promote cell
mediated inflammatory immune responses and are thought
to be important for development of many organ specific
autoimmune diseases.37 38 (b) Th2 type T cells produce IL-4,
IL-5, IL-10, and IL-13, and are thought to suppress
inflammation and help eosinophils and B cell antibody
production, and may play beneficial roles in human organ
specific inflammatory diseases.39 Th1 responses have been
shown to be important in EAN induction, whereas the
recovery phase is associated with a switch to Th2
responses.40 41
Overview of experiments
The importance of T cell reactivity to protein antigens of
peripheral myelin in GBS and CIDP remains unclear. To
define the frequency of these responses, we looked for
proliferative T cell reactivity to peptides of P0, P2, MBP, and
PMP-22 in a large group of patients with GBS and with CIDP,
and compared these with responses of healthy controls and
patients with ON.
We also used IFN-c and IL-5 ELISPOT assays in a smaller
subset of patients with GBS, CIDP, or ON and in healthy
controls to characterise frequencies of both spontaneous and
antigen specific cytokine secreting PBMC.
METHODS
Patients
The details of each patient group are shown in table 1.
Patients with GBS, CIDP, or ON were recruited from local
hospitals. Patients with GBS and those with CIDP fulfilled
standard diagnostic criteria.42 43 Patients with GBS had
predominantly demyelinating neuropathy and generally
made a prompt recovery. Patients with Miller Fisher
syndrome were excluded. Samples were collected from
patients with GBS within 10 days of the onset of neurological
symptoms, either before or at the peak of disease, and before
administration of any treatment. Patients with GBS were
graded on the GBS disability scale44 (table 2) and information
regarding potential precipitating factors including recent
infections or vaccinations was also recorded (table 2).
Patients with CIDP had not received any immunosuppress-
ive or immunomodulatory treatment for 2 months prior to
blood collection. For most of our patients with CIDP, blood
was collected when they were hospitalised for treatment of
relapses. Patients with ON included patients with hereditary
motor sensory, toxic, and diabetic neuropathy. All blood
samples were collected after informed, written consent was
obtained from each subject.
Myelin proteins and peptides
MBP was purified from human brain tissue.45 Peptides used
in the study were synthesised to .95% purity by Auspep
(Melbourne, Australia). Table 3 summarises the character-
istics of the antigens used in this study.
Proliferation assays
Proliferation assays using PBMC from each subject were
prepared using methods previously outlined.47 Briefly, 105
PBMC were cultured as quadruplicates with and without test
antigens (at 20 mg/ml) for 6 days, with 0.5 mCi 3H-thymidine
being added during the last 18 hours of culture. Thymidine
uptake was measured in counts per minute (cpm). The
stimulation index (SI) was determined by the formula:
SI= (mean cpm of antigen containing wells)/(mean cpm
of control wells)
A positive proliferative response was scored if the subject’s
cells responded to the antigen tested with an SI >2.0. Mean
and standard error values for background counts for each
subject group can be found in table 1.
ELISPOT assays
The numbers of spontaneous and antigen-specific IFN-c and
IL-5 secreting PBMC were determined using ELISPOT assays
in 16 patients with GBS, 7 with CIDP, 13 with ON, and 14
healthy controls.
PBMC to be tested in ELISPOT assays were pre-incubated
at 250 000 cells/well in 200 ml volumes of X-Vivo 15 media
(Cambrex, NJ, USA) in the presence of test peptides or
Table 1 Patient number and age details, and
proliferation assay background counts for patients with
GBS, CIDP, or ON and healthy control subjects
Patient
group
No.(men:
women)
Mean
age
(years)
Age
range
Median
age
Mean (SE)
assay
background
counts/min
GBS 64 (43: 21) 52 18–82 55 674 (93)
CIDP 54 (33: 21) 54 18–85 58 751 (130)
ON 62 (32: 30) 58 27–80 61 706 (107)
HC 83 (32: 51) 36 21–91 32 692 (75)
Table 2 GBS patient disease severity and
potential precipitating factors
n (%)
Disease severity
0 = healthy 0
1 =minor symptoms or signs 1 (1.7)
2 = independent ambulation 8 (13.8)
3 = able to walk 5 m with assistance 8 (13.8)
4 = chair or bed bound 24 (41.4)
5 = assisted ventilation required 17 (29.3)
6 = death 0
Potential precipitating factor
Upper respiratory tract infection 30 (50.8)
Gastrointestinal infections 10 (16.9)
Recent flu vaccinations 2 (3.4)
Epstein–Barr virus infection 1 (1.7)
Recent surgery 1 (1.7)
Uveitis 1 (1.7)
Fever of unknown origin 4 (6.7)
No identifiable precipitating factor 10 (16.9)
Of the 64 patients studied, GBS disability scale gradings
were recorded for 58 and information regarding potential
precipitating factors prior to the onset of neurological
symptoms was recorded for 59.
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proteins at 20 mg/ml as quadruplicates, or without antigens
as replicates of 12 wells, in 96 well, round bottomed, tissue
culture plates for 18 hours to maximise cell–cell contact for
antigen presentation. PBMC were then transferred to
ELISPOT assay plates for the detection of human IFN-c and
IL-5 secretion. ELISPOT assays were conducted according to
the manufacturer’s instructions (Mabtech, Sweden). The
average number per well of spot forming cells (SFC) for each
subject’s PBMC in the absence of antigen was calculated for
both IFN-c and IL-5, and for each subject this was used as a
measure of spontaneous cytokine production and expressed
as spontaneous SFC/106 PBMC. For each subject, and for
each of the cytokines, the average spontaneous SFC was
subtracted from the average SFC for PBMC in the presence of
each of the test antigens, to produce a corrected SFC for each
test antigen. Results were expressed as antigen specific SFC/
106 PBMC.
We used IL-5 rather than IL-4 ELISPOT assays as a
measure of T cell Th-2 cytokine secretion because IL-4 can be
produced by cells other than T cells.48
Statistical analysis
Proliferation assays
In the different subject groups, the percentages of individuals
making a positive proliferative response (SI >2.0) to test
peptides were compared using the x2 test with Yates’
correction applied as required. Proliferative T cell reactivity
to different antigens in the GBS or CIDP patient groups was
deemed to be of significance only if p values for comparisons
both with healthy controls and with patients with ON were
(0.05.
ELISPOT analysis of spontaneous and antigen
specific IFN-c and IL-5 secretion
ELISPOT data for both spontaneous and antigen specific IFN-
c and IL-5 secretion were found to be non-normally
distributed. The means +2SD of spontaneous cytokine
secretion and the means +2SD of antigen specific IFN-c
and IL-5 secretion in response to each antigen tested in the
healthy control group were calculated and used as cutoffs for
classifying data into positive and negative responses. This
enabled spontaneous cytokine secretion levels and antigen
specific reactivity within the four subject groups to each test
antigen, and to all test antigens collectively grouped, to be
compared by either x2 test with Yates’ correction or Fishers
exact test, and p(0.05 was deemed significant. Odds ratios
(OR) with 95% confidence intervals (CI) were also calculated
for significant comparisons.
RESULTS
T cell proliferation
The percentages of individuals in each subject group with a T
cell reactivity SI>2.0 were determined for each antigen (fig 1,
table 4) and compared by x2 analysis.
The percentage of patients with GBS reacting with an SI
>2.0 to whole MBP (35.9%) was comparable with that seen
in healthy controls (36.1%). The corresponding percentage of
patients with CIDP (16.7%) was significantly lower than that
of healthy controls (p=0.013), but not significantly different
from that of patients with ON. There was no statistically
significant difference in reactivity to MBP82–100 between any
of the test groups.
For PMP-2232–51, PMP-2241–61, and PMP-2251–64, no
statistically significant differences in reactivity were seen
between patients with GBS or CIDP, and healthy controls or
patients with ON. The proportion of patients with GBS
reacting to PMP-22120–133 (6.3%) was significantly lower than
healthy controls (20.7%, p=0.025), as was the proportion in
the ON disease group (6.5%) to PMP-22120–133 (p=0.031).
Reactivity in patients with CIDP (13.2%) was also lower than
that of healthy controls, although not significantly.
For P056–71 and P070–85, no statistically significant differ-
ences were seen between patients with GBS or CIDP, and
healthy controls or patients with ON. The proportion of
patients with GBS reacting to P0180–199 (19.6%) was
significantly higher than that of healthy controls (6.5%,
p=0.042), but not higher than patients with ON (14.8%).
Similarly, reactivity in patients with CIDP to P0180–199
(18.8%) was higher than that of healthy controls, but not
significantly (p=0.068).
No significant differences in proliferative reactivity to
either P214–25 or P261–70 were seen between patients with
GBS or CIDP, and healthy controls or patients with ON.
When GBS patient reactivity to either P214–25 or P261–70
(19%) was compared with the reactivity of healthy controls
and patients with ON grouped collectively (9%), significance
was reached (p=0.029). Similarly, reactivity of patients with
CIDP to either of these peptides (20.7%) was significantly
greater than that of healthy controls and patients with ON
grouped collectively (p = 0.018).
Table 3 Peptide and protein antigens tested in this study, including sequences and
numbering of residues within respective proteins
Peptide/protein
and sequence
range Peptide sequence Peptide description
PMP-2232–51 NGHATDLWQNCSTSSSGNVH Extracellular domain, overlaps PMP-2241–61
PMP-2241–61 NCSTSSSGNVHHCFSSSPNEW Extracellular domain, overlaps PMP-2232–51 and PMP-
2251–64
PMP-2251–64 HHCFSSSPNEWLQS Extracellular domain, overlaps PMP-2241–61
PMP-22120–133 RHPEWHLNSDYSYG Extracellular domain
P056–71 GQPYIDEVGTFKERIQ Extracellular domain, neuritogenic,
33 elicits human T cell
responses12
P070–85 IQWVGDPRWKDGSIV Extracellular domain, neuritogenic,
33 elicits human T cell
responses12
P0180–199 ASKRGRQTPVLYAMLDHSRS Cytoplasmic, C-terminus, neuritogenic,
33 elicits human T cell
responses12
P214–25 ENFDDYMKALGV Previously shown to elicit human T cell responses
11 12
P261–70 EISFKLGQEF Previously shown to elicit human T cell responses
11 12
MBP82–100 DENPVVHFFKNIVTPRTPP Immunodominant in humans, used in our previous MS
studies46
MBP Whole protein Human MBP, including all isoforms and charge isomers
Tetanus toxoid Whole toxoid protein Used as positive control as known strong inducer of T cell
responses
T cell reactivity in patients with GBS and CIPD 1433
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ELISPOT analysis
ELISPOT analysis of spontaneous IFN-c and IL-5
secretion
Numbers of ex vivo, spontaneous (in the absence of antigen)
IFN-c and IL-5 secreting PBMC were enumerated using
ELISPOT assays in 24 patients with GBS, 7 with CIDP, 13
with ON, and 14 healthy controls (fig 2).
The proportion of patients with CIDP with an increased
number of PBMC spontaneously secreting IFN-c (57.1%) was
significantly higher than that in healthy controls alone (7.1%,
p = 0.025), patients with ON alone (0%, p = 0.002), and in
grouped healthy controls and patients with ON (3.7%, p =
0.005, odds ratio (OR) =34.6, 95% confidence interval (CI)
2.8 to 420.2). The proportion of patients with GBS with an
increased number of PBMC spontaneously secreting IFN-c
(25.0%) was significantly higher than in grouped healthy
controls plus patients with ON (p=0.042, OR=8.7, 95% CI
1.9 to 78.3), and in patients with ON alone (p=0.048), but
bordered upon significance when compared with healthy
controls alone (p=0.07). Interestingly, the highest values of
spontaneous IFN-c secretion of all responses tested were seen
in five of the 24 patients with GBS tested.
The proportion of subjects with an increased number of
PBMC spontaneously secreting IL-5 was significantly higher
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Figure 1 Percentages of patients with
GBS, CIDP, or ON, and healthy
controls (HC) responding with a
proliferation assay SI >2.0 to specific
peptides and whole MBP.
Table 4 The percentages of individuals in each subject group with a T cell proliferation reactivity SI> 2.0 were determined for
each peptide or protein and compared by x2 analysis. Odds ratios (OR)with 95% confidence intervals (CI) were also calculated
for selected comparisons
Protein PMP-22 P0 P2 MBP
Peptide/protein 32–51 41–61 51–64 120-133 56–71 70–85 180-199 14–25 61–70
14–25 or
61–70 82-100 MBP
GBS (% +ve) 6.3 12.7 10.9 6.3 7.9 14.3 19.6 12.7 14.3 19.0 16.4 35.9
CIDP (% +ve) 15.1 1.9 17.0 13.2 7.7 11.3 18.8 9.4 15.1 20.8 20.8 16.7
HC (% +ve) 13.3 12.2 13.4 20.7 3.7 13.6 6.5 6.3 10.0 12.5 24.1 36.1
ON % +ve) 11.3 3.3 6.5 6.5 5.3 8.1 14.8 3.2 3.2 3.2 14.5 22.6
HC + ON (% +ve) 12.4 8.5 10.4 14.6 4.3 11.2 9.9 4.9 7.0 8.5 20.0 30.3
p for:
GBS v HC 0.264 0.927 0.651 0.025 0.452 0.903 0.042 0.298 0.431 0.281 0.260 0.979
GBS v OR – – – 0.25 – – 3.52 – – – – –
GBS v CI – – – 0.1–0.8 – – 1.1–11 – – – – –
GBS v ON 0.492 0.116 0.564 0.749 0.826 0.412 0.503 0.104 0.062 0.011 0.773 0.099
GBS v OR – – – – – – – – – 7.05 – –
GBS v CI – – – – – – – – – 1.5–33 – –
GBS v HC+ON 0.274 0.489 0.895 0.140 0.474 0.692 0.113 0.049 0.164 0.029 0.682 0.523
GBS v OR – – – – – – – 2.8 – 2.54 – –
GBS v CI – – – – – – – 0.9–8.1 – 1.1–6.0 – –
CIDP v HC 0.762 0.069 0.586 0.264 0.532 0.701 0.068 0.729 0.377 0.201 0.651 0.013
CIDP v OR – – – – – – – – – – – 0.35
CIDP v CI – – – – – – – – – – – 0.15–0.8
CIDP v ON 0.546 0.913 0.138 0.362 0.901 0.784 0.595 0.319 0.055 0.008 0.379 0.426
CIDP v OR – – – – – – – – – 7.8 – –
CIDP v CI – – – – – – – – – 1.6–37 – –
CIDP v HC+ON 0.797 0.189 0.315 0.987 0.570 0.819 0.181 0.406 0.147 0.018 0.934 0.078
CIDP v OR – – – – – – – – – 2.83 – –
CIDP v CI – – – – – – – – – 1.2-6.9 – –
HC v ON 0.722 0.116 0.280 0.031 0.972 0.441 0.203 0.663 0.21 0.095 0.153 0.078
HC v OR – – – 0.26 – – – – – – – –
HC v CI – – – 0.1–0.8 – – – – – – – –
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in patients with CIDP, but not those with GBS, compared
with healthy controls (p=0.048) and patients with ON
(p=0.008).
ELISPOT analysis of antigen specific IFN-c and IL-5
secretion
Numbers of ex vivo, background corrected, antigen specific
IFN-c and IL-5 secreting PBMC were determined using
ELISPOT assays in 16 patients with GBS, 7 with CIDP, 13
with ON, and 14 healthy controls (fig 3A, B). The proportions
of subjects in each of the four groups, and also in the
combined group of healthy controls and patients with ON,
with an increased number of PBMC producing IFN-c and IL-
5 in response to stimulation with individual peptides and
whole MBP are shown in table 5.
Antigen specific ELISPOT data for each cytokine were
initially analysed for each individual test antigen. Reactivity
to each antigen in patients with either GBS or CIDP was
compared with healthy controls alone, with patients with ON
alone, and with collectively grouped healthy controls and
patients with ON. The proportion of patients with GBS with
an increased number of PBMC producing IFN-c in response
to peptide P070–85 (25.0%) was significantly higher than
grouped healthy controls plus patients with ON (0%,
p=0.027, OR=9.0, 95% CI 0.90 to 82.6), but only
approached significance when compared with healthy con-
trols alone (p=0.066) and patients with ON alone
(p=0.077). The proportion of patients with CIDP with
increased numbers of PBMC producing IFN-c in response
to peptide PMP-2251–64 (57.1%) was significantly higher than
both healthy controls alone (p=0.025, OR=17.33, 95%
CI 1.38 to 216.6) and patients with ON alone (p=0.007,
OR = 18.66, 95% CI 1.50 to 232.3).
The proportion of patients with CIDP with increased
numbers of PBMC producing IFN-c in response to peptide
PMP-22120–133 (42.8 %) was significantly higher than that of
grouped healthy controls plus patients with ON (3.7%)
(p=0.021, OR=19.5, 95% CI 1.60 to 236.6), and of patients
with ON alone (p=0.031), but not that of healthy controls
alone (p=0.088).
No other significant differences in antigen specific IFN-c
production to any of the other individual peptides or whole
MBP were noted in either patients with GBS or patients with
CIDP compared with the grouped healthy controls and
patients with ON. No significant differences in antigen
specific IL-5 secretion were evident between patients with
either GBS or CIDP and the grouped healthy controls and
patients with ON using x2 analysis for comparison of
reactivity to individual test peptides.
As a second method for statistically analysing antigen
specific ELISPOT results, the GBS patient reactivity data for
all antigens tested were grouped into a combined dataset, as
were data for patients with CIDP or ON and healthy controls.
Analysis of this grouped data showed a significantly
increased proportion of antigen specific IFN-c secretion in
patients with GBS compared with healthy controls (p=0.03,
OR=2.30, 95% CI 1.02 to 5.16) and patients with ON
(p=0.03, OR=2.41, 95% CI 1.03 to 5.59). Similarly, antigen
specific IFN-c secretion in patients with CIDP was signifi-
cantly increased compared with healthy controls
(p=0.0000006, OR=6.8, 95% CI 2.98 to 15.76) and with
patients with ON (p=0.00000079, OR=7.18, 95% CI 3.02 to
17.05). No significant differences in antigen specific IL-5
secretion between either patients with GBS or patients with
CIDP and healthy controls or patients with ON were evident
using this grouped data analysis (fig 3B, table 5).
It is important to note that in any study involving a large
number of formal statistical tests, on average 1 in 20 com-
parisons will reach a significant p value of 0.05 by chance.
Correlation between peptide reactivity and GBS
disease severity
Patients with GBS were grouped into positive and negative
responders for antigen specific proliferation to peptides
derived from each peripheral myelin protein, and for
reactivity to any of the peptides tested. Mean GBS disability
scale values were calculated within each of the subgroups
(table 6). Interestingly, the subgroup of patients with GBS
with positive T cell reactivity to any of the PMP-22 peptides
had a statistically lower GBS disability score than the
subgroup of non-responding patients (p=0.003, t test).
Disability assessments were not made for patients with
CIDP at the time of blood collection, so no correlations could
be made for CIDP.
In patients with GBS, no statistically significant correlation
could be made linking reactivity to any of the antigens tested
with potential precipitating factors such as type of antecedent
infection.
DISCUSSION
In patients with GBS, CIDP, or ON and healthy controls, we
performed a detailed comparative study of T cell proliferative
reactivity and antigen specific ELISPOT IFN-c and IL-5
secretion in response to antigenic stimulation with peptides
derived from P0, P2, PMP-22, and MBP. We also compared
the numbers of PBMC spontaneously secreting IFN-c and IL-
5 in patients with GBS or CIDP with those in healthy controls
and patients with ON.
Proliferation assay reactivity
No statistically significant elevations in frequencies of
antigen specific proliferation assay reactivity to any of the
antigens tested were seen in patients with GBS or CIDP
compared with both healthy controls and patients with ON.
The proportion of patients with GBS reacting to P0180–199 was
significantly higher than that of healthy controls, but not
patients with ON. There was some increase in reactivity to P2
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Figure 2 Scatter plot of the numbers of spontaneous IFN-c and IL-5
secreting PBMC in patients with GBS, CIDP, or ON, and in healthy
controls. The short horizontal lines represent the threshold cutoffs for
positive responses. Results are expressed as spot forming cells (SFC) per
106 PBMC.
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Figure 3 Scatter plot of antigen
specific (A) IFN-c and (B) IL-5 secretion
after stimulation of PBMC with each of
the test antigens in patients with GBS,
CIDP, or ON, and healthy controls
(HC). Background numbers of PBMC
spontaneously producing IFN-c or IL-5
in the absence of antigen have been
subtracted for each data point. The
short horizontal lines represent the
threshold cutoffs for positive responses
to each antigen tested. Results are
expressed as spot forming cells (SFC)
per 106 PBMC. For sequences of
peptides tested, refer to table 3.
Table 5 Percentages of patients with GBS, CIDP, or ON and healthy controls (HC) responding with positive antigen specific
ELISPOT IFN-c and IL-5 reactivity to specific peptides and whole MBP
Antigen specific cytokine secretion
PMP22 P0 P2 MBP
32–51 41–61 51–64 120–133 56–71 70–85 180–199 14–25 61–70 82–100 Whole
All
antigens
IFN-c
Threshold 7.7 10.9 13.8 12.9 26.4 11.6 8.5 8.1 18.9 16.4 20.3
GBS 18.7 12.5 12.5 6.2 12.5 25.0 12.5 0 18.7 12.5 6.2 12.5
CIDP 42.8 28.5 57.1 42.8 14.2 14.2 14.2 42.8 14.2 28.5 28.5 29.9
HC 7.1 7.1 7.1 7.1 7.1 0 7.1 0 7.1 7.1 7.1 5.8
ON 7.7 15.4 0 0 0 0 7.7 15.4 0 7.7 7.7 5.6
HC+ON 7.4 11.1 3.7 3.7 3.7 0 7.4 7.4 3.7 7.4 7.4 5.7
IL-5
Threshold 11.2 4.4 31.9 7.6 5.9 16.3 6.3 9.8 6.3 13.3 12.8
GBS 0 6.3 0 6.3 18.8 0 12.5 6.3 0 0 12.5 5.7
CIDP 0 28.6 0 14.3 28.6 0 14.3 14.3 14.3 14.3 14.3 13.0
HC 7.1 7.1 7.1 7.1 14.3 14.3 7.1 7.1 7.1 7.1 7.1 8.4
ON 0 21.4 0 7.1 14.2 0 7.1 0 7.1 0 0 5.2
HC+ON 3.6 14.3 3.6 7.1 14.3 7.1 7.1 3.6 7.1 3.6 3.6 6.8
Results from cells/106 PBMC. The healthy control mean+2SD of antigen specific PBMC for each of the test antigens was used as a threshold to classify responses
into positive or negative for each subject. Threshold values are expressed as antigen specific cells/106 PBMC.
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and P0 peptides in both patients with GBS and those with
CIDP, but this was not statistically significant.
This study was not an exhaustive search for T cell epitope
specificity within peripheral myelin proteins. There may be T
cells of pathological importance in GBS and CIDP specific to
other epitopes within P0, P2, and PMP-22 that were not
encompassed by the peptides selected for study in this
project, or specific for other peripheral nerve myelin antigens.
We previously found significantly increased PBMC prolifera-
tive reactivity to the ganglioside GM1 in patients with GBS,49
and it may be that glycolipid antigens also serve as targets of
autoreactivity.
Interestingly, we found that patients with GBS with
positive proliferative reactivity to PMP-22 peptides as a group
had significantly less severe disease than patients not
responding to these peptides. We previously found a similar
correlation, in that patients with GBS with anti-GM1 T cell
reactivity were significantly less likely to need mechanical
ventilation than those without such reactivity.49 This raises
the possibility that T cells specific for certain peripheral nerve
components, such as PMP-22 and GM1, might have an
immunoregulatory or neuroprotective role.
Th1 versus Th2 cytokines in GBS
In patients with GBS, we found significantly increased
numbers of PBMC spontaneously secreting IFN-c compared
with grouped healthy controls plus patients with ON, and to
patients with ON alone. Although comparisons with healthy
controls alone only bordered upon significance, the highest
values of spontaneous IFN-c secretion were seen in five of the
24 tested patients with GBS. These cells are presumably
reacting to in vivo stimulation with unknown peptide or
ganglioside antigens. They may be contributing to the
immunopathogenesis of GBS in some patients, or may persist
as a consequence of T cell activation by the antecedent
infections which commonly precede GBS.4 5 It may be that T
cells secreting pro-inflammatory Th1 type cytokines are
important in the early stages of disease in some patients
with GBS, possibly reducing in numbers by the time
neurological symptoms are evident. Blood was collected from
patients in our study soon after the onset of neurological
symptoms, sometimes within 2 days.
In patients with GBS, we found a significantly higher
proportion of subjects with an increased number of PBMC
secreting IFN-c in response to all test antigens grouped
collectively compared with healthy controls alone and
patients with ON alone, and in response to P070–85 compared
with grouped healthy controls plus patients with ON, but
none of the responses to individual test antigens in patients
with GBS was significantly higher than in both healthy
controls alone and in patients with ON alone.
There are conflicting reports of elevated levels of sponta-
neous and antigen specific Th1 and Th2 cytokine secreting
cells in early GBS,50–53 and several studies outline an
increasing involvement for Th2 cytokine secreting cells in
the recovery stages of GBS.54 55 It has been postulated that IL-
4 (Th2) responses are beneficial in GBS, and may have a role
in disease termination through downregulation of Th1
responses.39 54 Conversely, Th2 cytokines may induce allergic
disease by helping B cells produce potentially pathogenic
allergen specific IgE,51 which is reportedly increased in both
GBS and CIDP.56 GBS is usually a self limiting disease, and
Th2 cytokine production has been reported in other diseases
that resolve spontaneously such as reactive arthritis.57
However, in our study, both antigen specific and spontaneous
levels of IL-5 secretion in patients with GBS did not differ
significantly from healthy controls and patients with ON. We
tested GBS subjects only in the early stage of disease, so we
were unable to enumerate Th2 cytokine producing cells in the
recovery phase of GBS.
Th1 versus Th2 cytokines in CIDP
We have shown significantly increased numbers of PBMC
spontaneously secreting IFN-c and IL-5 in patients with
CIDP. We also found a significantly higher proportion of
patients with CIDP with increased numbers of PBMC
secreting IFN-c in response to PMP-2251–64 and in response
to all test antigens grouped collectively compared with
healthy controls alone and patients with ON alone. Of the
four patients with CIDP with increased numbers of PBMC
secreting IFN-c in response to PMP-2251–64, only one showed
positive proliferative reactivity to this peptide, emphasising
the increased detection sensitivity of ELISPOT IFN-c assays.
For many of our patients with CIDP, blood was collected
when they were hospitalised for treatment of active disease
exacerbation. A difference in cytokine profiles between the
exacerbation and remission stages of CIDP has been
reported.58 Our finding of increased numbers of spontaneous
Th1 IFN-c and Th2 IL-5 secreting cells in patients with CIDP
is partly at odds with a previous report of increased
proportions of only Th2-IL-4 secreting CD4+T cells in the
peripheral blood of 12 patients with CIDP.51 We found
increased numbers of spontaneous, but not antigen specific,
IL-5 secreting PBMC in patients with CIDP compared with
healthy controls and patients with ON. Others have found
increased levels of both the Th1 (IFN-c) and Th2 (IL-4)
cytokines in the exacerbation stage of CIDP, but an elevation
of only IL-4 secreting Th2 cells in remission.58 It is important
to note that our ELISPOT methodology detected IL-5 rather
than IL-4 as a measure of Th2 cytokine secretion. CIDP
patient cells tested in ELISPOT assays were all collected
during exacerbations, so we were unable to assess numbers
of Th1 and Th2 cytokine producing cells during remission.
Measurements of both spontaneous and antigen specific
cytokine secreting cells in the peripheral blood may under-
represent the importance of these cells in both GBS and
CIDP. Their numbers in the peripheral blood may be reduced
because of homing to the peripheral nervous system, perhaps
even before the onset of neurological symptoms.
We have shown that T cells specific for peripheral myelin
peptides are present in the blood of patients with CIDP at low
frequencies. It may be possible that these low levels of T cells,
upon crossing the blood–nerve barrier and coming into
contact with their respective antigens in the endoneural
compartment, are further activated to proliferate and produce
pro-inflammatory cytokines and chemokines. This may then
be sufficient to increase blood–nerve barrier permeability to
antibody,59 with resultant complement fixation and other
pro-inflammatory immunological processes.
Table 6 Correlations between GBS patient T
cell peptide reactivity and disease severity
GBS patient subgroup n
Mean (SE)
disability
score p value*
PMP 22+ 15 3.13 (0.3) 0.003
PMP 22– 43 4.04 (0.14)
P0+ 17 3.52 (0.26) 0.192
P02 41 3.92 (0.16)
P2+ 9 3.33 (0.39) 0.139
P22 49 3.89 (0.14)
MBP82–100 or MBP+ 21 3.47 (0.25) 0.067
MBP82–100 or MBP2 37 4.00 (0.16)
Any peptide+ 27 3.44 (0.21) 0.012
All peptide 2 31 4.12 (0.17)
*t test.
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CONCLUSIONS
Our findings of increased numbers of spontaneous IFN-c
secreting PBMC in 25% of patients with GBS suggests that
Th1 cells may play a role in the pro-inflammatory disease
process in early GBS, although the specificity of these cells
remains to be determined. Significantly increased levels of
both spontaneous and antigen specific IFN-c secretion, as
well as increased spontaneous IL-5 secretion in patients with
CIDP, suggest that T cells present in the blood of patients
with CIDP have both pro-inflammatory and immunoregula-
tory potential.
Although significantly increased numbers of PMP-2251–64
specific IFN-c secreting PBMC were found in patients with
CIDP, the frequencies of these cells were generally lower than
1 in 10 000 cells, and this low level reactivity was not
detected in proliferation assays.
Further careful analysis of T cell epitopic specificity and
Th1/Th2 cytokine secretion profiles in the blood from early
disease through to recovery in patients with GBS, and in
exacerbations and remissions of CIDP are required to shed
further light on the roles of peripheral myelin reactive T cells
in these diseases.
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Simulconsult: www.simulconsult.com
I
magine the scene: you have just seen
a patient with what seems likely to be
an inherited or congenital syndrome
who has a combination of symptoms
and signs you do not recognise and in
whom standard investigations have
provided no clues. What do you do?
Looking in the books is very time
consuming and depends on how well
the books are indexed; searching
PubMed or online inheritance in man
(OMIM) is often difficult using just
symptoms and signs. Wouldn’t it be
useful if you could put the clinical
information into a database to narrow
down the differential diagnosis?
This is the idea that drives www.
simulconsult.com, which describes itself
as a ‘‘medical decision support soft-
ware’’ that ‘‘allows doctors and other
medical professionals to combine clin-
ical and laboratory findings’’ and get a
‘‘simultaneous consult about diagno-
sis’’. Registration is straightforward
and this leads you to an introductory
video and the opportunity to search the
site. The searching is reasonably intui-
tive. You enter the age and sex, and then
can add clinical feature and test results,
either having searched for them or from
an alphabetical or category based pick
list. The terms used are not always what
you expect, so I found myself using the
alphabetical list.
Once you have your primary features
you then go to a differential diagnosis
page, with the diagnoses listed (exhaus-
tively) in a bar graph in order of
likelihood. You can then pick out the
disease profile and mark other features
as present or absent, which results in
reordering of the differential diagnosis.
Further information for each disease,
such as incidence and age of onset, is
easily found.
The idea is very attractive – but does it
work? The package available is ‘‘neuro-
logical syndromes’’, which is described
as a beta version of inherited and
congenital problems. Searching simple
problems highlighted the diagnoses you
would first consider. When searching
using details of patients with more
obscure problems I found the differen-
tial diagnoses lists helpful and diagnos-
tic possibilities that would otherwise
have taken some time to consider were
raised. The ability to review the features
of each condition, especially rarer syn-
dromic diagnoses, was particularly
helpful. I think this search tool should
lead to a more focussed approach to
investigating patients with suspected
metabolic or genetic syndromes.
This site is acknowledged to be in
development, and I expect this will
further refine the terms used to describe
the clinical picture—which do not
always match the usual neurological
terms—but also the relative likelihood
of the differential diagnoses offered.
I found the site useful and I will be
visiting again.
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